Polycystic Ovary Syndrome is being renamed Polyendocrine Metabolic Ovarian Syndrome to more accurately describe the disorder's hormonal and metabolic characteristics.
The change in terminology aims to reduce diagnostic errors. Because the previous name focused on ovarian cysts, many patients were missed or misdiagnosed when those specific symptoms were not present.
Medical experts discussed the transition on the Pakistani morning show Subh Ka Samaa, hosted by Madeha Naqvi. During the segment, doctors presented various treatment options for irregular periods, a common symptom of the disorder.
The rebranding addresses a fundamental inaccuracy in how the condition was categorized. An Endocrine Society representative said, "The old name, often shortened to PCOS, is inaccurate" [1]. By shifting the focus toward the endocrine and metabolic systems, the new name, PMOS, highlights that the syndrome is a systemic issue rather than one limited to the ovaries.
This condition is widespread, affecting tens of millions of women worldwide [2]. The shift in nomenclature is intended to help clinicians identify the syndrome earlier by looking for metabolic markers, rather than relying solely on the presence of cysts.
Reports of the name change began appearing in global health media earlier this month [1]. The transition reflects a growing understanding of how hormonal imbalances drive the metabolic dysfunction associated with the syndrome.
“The old name, often shortened to PCOS, is inaccurate.”
The transition from PCOS to PMOS represents a shift in clinical priority from morphology—how an organ looks on an ultrasound—to physiology—how the body functions metabolically. By removing the emphasis on 'cysts,' which are not present in every patient, the medical community intends to broaden the diagnostic net and ensure women with metabolic symptoms receive treatment even if their ovaries appear normal.
